Journal of Medicinal Chemistry · 2007 · 37 citations · 10 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyProdrug DesignAntiviral PharmacologyAntiviral Prodrug DesignAntiviral TherapyEnzyme InhibitionViral HepatitisViral Hepatitis TreatmentAdenosine Deaminase TherapyDegradationLiver-targeted ProdrugsNucleoside Analogue AntiviralsNucleoside Analogue TherapyNucleotide Analogue ProdrugsPolymerase Inhibitor ProdrugsPrimary Hepatocyte Assays
2'-C-Methyladenosine exhibits impressive inhibitory activity in the cell-based hepatitis C virus (HCV) subgenomic replicon assay, by virtue of intracellular conversion to the corresponding nucleoside triphosphate (NTP) and inhibition of NS5B RNA-dependent RNA polymerase (RdRp). However, rapid degradation by adenosine deaminase (ADA) limits its overall therapeutic potential. To reduce ADA-mediated deamination, we prepared cyclic 1-aryl-1,3-propanyl prodrugs of the corresponding nucleoside monophosphate (NMP), anticipating cytochrome P450 3A-mediated oxidative cleavage to the NMP in hepatocytes. Lead compounds identified in a primary rat hepatocyte screen were shown to result in liver levels of NTP predictive of efficacy after intravenous dosing to rats. The oral bioavailability of the initial lead was below 5%; therefore, additional analogues were synthesized and screened for liver NTP levels after oral administration to rats. Addition of a 2',3'-carbonate prodrug moiety proved to be a successful strategy, and the 1-(4-pyridyl)-1,3-propanyl prodrug containing a 2',3'-carbonate moiety displayed oral bioavailability of 39%.
10
Keith Biggadike, Richard Angell, Colin M. Burgess et al. · Journal of Medicinal Chemistry · 1999 · 180 citations · Full text